Latest & greatest articles for copd exacerbations

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on copd exacerbations or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on copd exacerbations and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for copd exacerbations

1. Adding low dose theophylline to inhaled corticosteroids does not reduce COPD exacerbations

Adding low dose theophylline to inhaled corticosteroids does not reduce COPD exacerbations Adding low dose theophylline to inhaled corticosteroids does not reduce COPD exacerbations Dissemination Centre Discover Portal NIHR DC Discover Adding low dose theophylline to inhaled corticosteroids does not reduce COPD exacerbations Published on 15 January 2019 doi: Taking low-dose theophylline tablets in addition to inhaled corticosteroids did not significantly reduce (...) chronic obstructive pulmonary disease flare-ups (exacerbations). This NIHR funded study found that people taking the combination and those taking an inhaled steroid had the same number of exacerbations - just over two per year. People who experience frequent exacerbations are often prescribed steroid inhalers to reduce inflammation of the airways. Theophylline also helps open up the airways, but the amount needed to be effective can produce unwanted side effects. Some earlier evidence suggested that low-dose theophylline might

NIHR Dissemination Centre2019

2. People with COPD exacerbations prefer early discharge then treatment at home

People with COPD exacerbations prefer early discharge then treatment at home Hospital at home treatment for COPD flare-ups Dissemination Centre Discover Portal NIHR DC Discover People with COPD exacerbations prefer early discharge then treatment at home Published on 11 December 2018 doi: People with flare-ups of COPD (chronic obstructive pulmonary disease) prefer to be managed at home rather than in hospital. Hospital stay was on average four days shorter when people were discharged early (...) known as an exacerbation. In 2017–18 in England, there were 34,980 hospital admissions for acute exacerbations of COPD, totalling 137,099 days in hospital. Hospital at home services can provide much, but not all, of the care available in hospital and has been shown effective, but choosing appropriate patients has been difficult. This study aimed to see if treating people at home was effective and cheaper for people at low risk of dying from an exacerbation of COPD according to the DECAF clinical

NIHR Dissemination Centre2019

3. COPD exacerbation: no systematic use of antibiotics

COPD exacerbation: no systematic use of antibiotics Prescrire IN ENGLISH - Spotlight ''COPD exacerbation: no systematic use of antibiotics'', 1 January 2019 {1} {1} {1} | | > > > COPD exacerbation: no systematic use of antibiotics Spotlight Every month, the subjects in Prescrire’s Spotlight. 100 most recent :  |   |   |   |   |   |   |   |   |  Spotlight COPD exacerbation: no systematic use of antibiotics For episodes (...) of moderate aggravation in patients with chronic obstructive pulmonary disease (COPD), it is preferable to prescribe antibiotics as a first-line treatment only when the suspicion of bacterial infection is reinforced by an increase in sputum purulence. Patients with chronic obstructive pulmonary disease (COPD) are subject to exacerbations of their disease, i.e. episodes of prolonged aggravation. The known causes are mainly viral and bacterial infections. Some exacerbations justify hospitalisation: severe

Prescrire2019

4. Nebulized terbutaline & ipratropium bromide vs terbutaline alone in acute exacerbation of COPD requiring noninvasive ventilation: a randomized double blind controlled trial

Nebulized terbutaline & ipratropium bromide vs terbutaline alone in acute exacerbation of COPD requiring noninvasive ventilation: a randomized double blind controlled trial 30156361 2018 10 22 1553-2712 2018 Aug 29 Academic emergency medicine : official journal of the Society for Academic Emergency Medicine Acad Emerg Med Nebulized Terbutaline and Ipratropium Bromide Versus Terbutaline Alone in Acute Exacerbation of Chronic Obstructive Pulmonary Disease Requiring Noninvasive Ventilation (...) : A Randomized Double-blind Controlled Trial. 10.1111/acem.13560 Short-acting β 2 -agonists are the mainstay of treatment of patients with acute exacerbation of chronic obstructive pulmonary disease (AECOPD) in the emergency department (ED). It is still unclear whether the addition of short-acting anticholinergics is clinically more effective care compared to treatment with β 2 -agonists alone in patients with hypercapnic AECOPD. The objective was to evaluate whether combining ipratropium bromide (IB

EvidenceUpdates2018

5. Effect of Theophylline as Adjunct to Inhaled Corticosteroids on Exacerbations in Patients With COPD: A Randomized Clinical Trial.

Effect of Theophylline as Adjunct to Inhaled Corticosteroids on Exacerbations in Patients With COPD: A Randomized Clinical Trial. Importance: Chronic obstructive pulmonary disease (COPD) is a major global health issue and theophylline is used extensively. Preclinical investigations have demonstrated that low plasma concentrations (1-5 mg/L) of theophylline enhance antiinflammatory effects of corticosteroids in COPD. Objective: To investigate the effectiveness of adding low-dose theophylline (...) to inhaled corticosteroids in COPD. Design, Setting, and Participants: The TWICS (theophylline with inhaled corticosteroids) trial was a pragmatic, double-blind, placebo-controlled, randomized clinical trial that enrolled patients with COPD between February 6, 2014, and August 31, 2016. Final follow-up ended on August 31, 2017. Participants had a ratio of forced expiratory volume in the first second to forced vital capacity (FEV1/FVC) of less than 0.7 with at least 2 exacerbations (treated

JAMA2018

6. Use of adjunct cardiovascular therapy in patients hospitalised for acute exacerbations of COPD

Use of adjunct cardiovascular therapy in patients hospitalised for acute exacerbations of COPD 30221169 2018 11 14 2312-0541 4 3 2018 Jul ERJ open research ERJ Open Res Use of adjunct cardiovascular therapy in patients hospitalised for acute exacerbations of COPD. 00087-2018 10.1183/23120541.00087-2018 In real-life practice, acute exacerbation of COPD is often treated as a cardiopulmonary syndrome http://ow.ly/uAnk30luMYz. Roversi Sara S Dept of Medical and Surgical Sciences, University

ERJ open research2018 Full Text: Link to full Text with Trip Pro

7. Circulating eosinophil levels do not predict severe exacerbations in COPD: a retrospective study

Circulating eosinophil levels do not predict severe exacerbations in COPD: a retrospective study 30083552 2018 11 14 2312-0541 4 3 2018 Jul ERJ open research ERJ Open Res Circulating eosinophil levels do not predict severe exacerbations in COPD: a retrospective study. 00022-2018 10.1183/23120541.00022-2018 Whether the level of circulating eosinophils in chronic obstructive pulmonary disease (COPD) patients can predict the risk of exacerbations of COPD (ECOPD) or response to treatment is debated (...) stability and hospitalisation, as well as clinical and functional data and the relation to recurrent exacerbations were analysed. We studied 992 COPD patients (318 ECOPD patients and 674 controls). Among ECOPD patients, 121 had one or more ECOPD during the year after the index event. The prevalence of eosinophils ≥2% was 72% in ECOPD patients and 71% in controls (p=0.93). Among ECOPD patients, eosinophil levels ≥2%, ≥4% or ≥300 cells·μL -1 , either when clinically stable or during hospitalisation, did

ERJ open research2018 Full Text: Link to full Text with Trip Pro

8. COPD exacerbations

COPD exacerbations Top results for copd exacerbations - Trip Database or use your Google+ account Turning Research Into Practice My query is: English Français Deutsch Čeština Español Magyar Svenska ALL of these words: Title only Anywhere in the document ANY of these words: Title only Anywhere in the document This EXACT phrase: Title only Anywhere in the document EXCLUDING words: Title only Anywhere in the document Timeframe: to: Combine searches by placing the search numbers in the top search (...) box and pressing the search button. An example search might look like (#1 or #2) and (#3 or #4) Loading history... Population: Intervention: Comparison: Outcome: Population: Intervention: Latest & greatest articles for copd exacerbations The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic

Trip Latest and Greatest2018

9. Home treatment of COPD exacerbation selected by DECAF score: a non-inferiority, randomised controlled trial and economic evaluation

Home treatment of COPD exacerbation selected by DECAF score: a non-inferiority, randomised controlled trial and economic evaluation 29680821 2018 04 22 1468-3296 2018 Apr 21 Thorax Thorax Home treatment of COPD exacerbation selected by DECAF score: a non-inferiority, randomised controlled trial and economic evaluation. thoraxjnl-2017-211197 10.1136/thoraxjnl-2017-211197 Previous models of Hospital at Home (HAH) for COPD exacerbation (ECOPD) were limited by the lack of a reliable prognostic (...) Upon Tyne, UK. eng Journal Article 2018 04 21 England Thorax 0417353 0040-6376 copd exacerbations Competing interests: SCB reports grants from NIHR: Research for Patient Benefit Programme, during the conduct of the study; HTA funding, grants from Philips Respironics and Pfizer Open Air, personal fees from Pfizer and AstraZeneca, outside the submitted work. JG reports grants from NIHR Research for Patient Benefit, during the conduct of the study. CE, GJG, TH, AJS and JS have no competing interests

EvidenceUpdates2018

10. The feasibility of early pulmonary rehabilitation and activity after COPD exacerbations: external pilot randomised controlled trial, qualitative case study and exploratory economic evaluation

The feasibility of early pulmonary rehabilitation and activity after COPD exacerbations: external pilot randomised controlled trial, qualitative case study and exploratory economic evaluation The feasibility of early pulmonary rehabilitation and activity after COPD exacerbations: external pilot randomised controlled trial, qualitative case study and exploratory economic evaluation Journals Library An error occurred retrieving content to display, please try again. >> >> >> Page Not Found Page

NIHR HTA programme2018

11. Do antibiotics improve outcomes for patients hospitalized with COPD exacerbations?

Do antibiotics improve outcomes for patients hospitalized with COPD exacerbations? Do antibiotics improve outcomes for patients hospitalized with COPD exacerbations? Toggle navigation Shared more. Cited more. Safe forever. Toggle navigation View Item JavaScript is disabled for your browser. Some features of this site may not work without it. Search MOspace This Collection Browse Statistics Do antibiotics improve outcomes for patients hospitalized with COPD exacerbations? View/ Open Date 2012-09 (...) Format Metadata Abstract Antibiotic use reduced mortality and treatment failure in patients hospitalized with acute exacerbations of chronic obstructive pulmonary disease (COPD) (strength of recommendation [SOR]: A, systematic reviews of randomized controlled trials [RCTs]). Giving antibiotics early to hospitalized patients decreased the need for later ventilation and readmission within 30 days for exacerbation of COPD (SOR: B, a retrospective cohort study). URI Citation Journal of Family

Clinical Inquiries2018

12. Effect of erdosteine on the rate and duration of COPD exacerbations: the RESTORE study

Effect of erdosteine on the rate and duration of COPD exacerbations: the RESTORE study 29025888 2017 12 19 1399-3003 50 4 2017 Oct The European respiratory journal Eur. Respir. J. Effect of erdosteine on the rate and duration of COPD exacerbations: the RESTORE study. 1700711 10.1183/13993003.00711-2017 Oxidative stress contributes to chronic obstructive pulmonary disease (COPD) exacerbations and antioxidants can decrease exacerbation rates, although we lack data about the effect of such drugs (...) on exacerbation duration.The RESTORE (Reducing Exacerbations and Symptoms by Treatment with ORal Erdosteine in COPD) study was a prospective randomised, double-blind, placebo-controlled study, enrolling patients aged 40-80 years with Global Initiative for Chronic Obstructive Lung Disease stage II/III. Patients received erdosteine 300 mg twice daily or placebo added to usual COPD therapy for 12 months. The primary outcome was the number of acute exacerbations during the study.In the pre-specified intention

EvidenceUpdates2018 Full Text: Link to full Text with Trip Pro

13. Management of COPD exacerbations: a European Respiratory Society/American Thoracic Society guideline

Management of COPD exacerbations: a European Respiratory Society/American Thoracic Society guideline Management of COPD exacerbations: a European Respiratory Society/American Thoracic Society guideline | European Respiratory Society Main menu User menu Search Search for this keyword Search for this keyword Management of COPD exacerbations: a European Respiratory Society/American Thoracic Society guideline Jadwiga A. Wedzicha (ERS co-chair) , Marc Miravitlles , John R. Hurst , Peter M.A (...) of chronic obstructive pulmonary disease (COPD) exacerbations. Comprehensive evidence syntheses, including meta-analyses, were performed to summarise all available evidence relevant to the Task Force's questions. The evidence was appraised using the Grading of Recommendations, Assessment, Development and Evaluation approach and the results were summarised in evidence profiles. The evidence syntheses were discussed and recommendations formulated by a multidisciplinary Task Force of COPD experts. After considering the balance

European Respiratory Society2017

14. Home-based maintenance tele-rehabilitation reduces the risk for acute exacerbations of COPD, hospitalisations and emergency department visits

Home-based maintenance tele-rehabilitation reduces the risk for acute exacerbations of COPD, hospitalisations and emergency department visits 28546268 2017 05 26 2017 05 26 1399-3003 49 5 2017 May The European respiratory journal Eur. Respir. J. Home-based maintenance tele-rehabilitation reduces the risk for acute exacerbations of COPD, hospitalisations and emergency department visits. 1602129 10.1183/13993003.02129-2016 Pulmonary rehabilitation (PR) remains grossly underutilised by suitable (...) patients worldwide. We investigated whether home-based maintenance tele-rehabilitation will be as effective as hospital-based maintenance rehabilitation and superior to usual care in reducing the risk for acute chronic obstructive pulmonary disease (COPD) exacerbations, hospitalisations and emergency department (ED) visits.Following completion of an initial 2-month PR programme this prospective, randomised controlled trial (between December 2013 and July 2015) compared 12 months of home-based

EvidenceUpdates2017

15. Colistin for Prophylactic Use in Non-Cystic Fibrosis Bronchiectasis or COPD with Exacerbations: A Review of Clinical and Cost-Effectiveness and Guidelines

Colistin for Prophylactic Use in Non-Cystic Fibrosis Bronchiectasis or COPD with Exacerbations: A Review of Clinical and Cost-Effectiveness and Guidelines Colistin for Prophylactic Use in Non-Cystic Fibrosis Bronchiectasis or COPD with Exacerbations: A Review of Clinical and Cost-Effectiveness and Guidelines | CADTH.ca Find the information you need Colistin for Prophylactic Use in Non-Cystic Fibrosis Bronchiectasis or COPD with Exacerbations: A Review of Clinical and Cost-Effectiveness (...) and Guidelines Colistin for Prophylactic Use in Non-Cystic Fibrosis Bronchiectasis or COPD with Exacerbations: A Review of Clinical and Cost-Effectiveness and Guidelines Published on: June 27, 2017 Project Number: RC0896-000 Product Line: Research Type: Drug Report Type: Summary with Critical Appraisal Result type: Report Question What is the clinical effectiveness of colistin for the prophylactic treatment of adults with either non-cystic fibrosis bronchiectasis or patients

Canadian Agency for Drugs and Technologies in Health - Rapid Review2017

16. Effect of Home Noninvasive Ventilation With Oxygen Therapy vs Oxygen Therapy Alone on Hospital Readmission or Death After an Acute COPD Exacerbation: A Randomized Clinical Trial.

Effect of Home Noninvasive Ventilation With Oxygen Therapy vs Oxygen Therapy Alone on Hospital Readmission or Death After an Acute COPD Exacerbation: A Randomized Clinical Trial. Importance: Outcomes after exacerbations of chronic obstructive pulmonary disease (COPD) requiring acute noninvasive ventilation (NIV) are poor and there are few treatments to prevent hospital readmission and death. Objective: To investigate the effect of home NIV plus oxygen on time to readmission or death in patients (...) with persistent hypercapnia after an acute COPD exacerbation. Design, Setting, and Participants: A randomized clinical trial of patients with persistent hypercapnia (Paco2 >53 mm Hg) 2 weeks to 4 weeks after resolution of respiratory acidemia, who were recruited from 13 UK centers between 2010 and 2015. Exclusion criteria included obesity (body mass index [BMI] >35), obstructive sleep apnea syndrome, or other causes of respiratory failure. Of 2021 patients screened, 124 were eligible. Interventions

JAMA2017 Full Text: Link to full Text with Trip Pro

17. Procalcitonin and CRP as Biomarkers in Discrimination of Community-acquired Pneumonia and Exacerbation of COPD

Procalcitonin and CRP as Biomarkers in Discrimination of Community-acquired Pneumonia and Exacerbation of COPD 28680355 2018 11 13 1452-8258 36 2 2017 Apr Journal of medical biochemistry J Med Biochem Procalcitonin and CRP as Biomarkers in Discrimination of Community-acquired Pneumonia and Exacerbation of COPD. 122-126 10.1515/jomb-2017-0011 Serum procalcitonin (PCT) and C-reactive protein (CRP) are markers of systemic inflammation and bacterial infection. We aimed to compare the usefulness (...) of procalcitonin and CRP in patients with community-acquired pneumonia and exacerbations of chronic obstructive pulmonary disease (COPD). A total of 116 consecutive patients were included in the study: 76 with chronic obstructive pulmonary disease in group 1, and 40 with pneumonia in group 2. Median serum CRP level was 44 mg/L in the COPD group and 132 mg/L in the pneumonia group. Median value of serum PCT was found to be 0.07 in the COPD group and 0.14 ng/mL in the pneumonia group. Serum PCT and CRP levels

Journal of medical biochemistry2017 Full Text: Link to full Text with Trip Pro

18. β-blockers in exacerbations of COPD: feasibility of a randomised controlled trial.

β-blockers in exacerbations of COPD: feasibility of a randomised controlled trial. 28154818 2017 02 03 2017 02 24 3 1 2017 Jan ERJ open research ERJ Open Res β-blockers in exacerbations of COPD: feasibility of a randomised controlled trial. 00090-2016 10.1183/23120541.00090-2016 A feasibility randomised controlled trial of β-blockers in acute exacerbations of COPD http://ow.ly/lVcy305B36D. Chang Catherina L CL Respiratory Research Unit, Dept of Respiratory Medicine, Waikato Hospital, Hamilton

ERJ open research2017 Full Text: Link to full Text with Trip Pro

20. Prevention of COPD Exacerbations: An Official ERS/ATS Clinical Practice Guideline

Prevention of COPD Exacerbations: An Official ERS/ATS Clinical Practice Guideline Prevention of COPD exacerbations: a European Respiratory Society/ American Thoracic Society guideline Jadwiga A. Wedzicha (ERS co-chair) 1 , Peter M.A. Calverley 2 , Richard K. Albert 3 , Antonio Anzueto 4 , Gerard J. Criner 5 , John R. Hurst 6 , Marc Miravitlles 7 , Alberto Papi 8 , Klaus F. Rabe 9 , David Rigau 10 , Pawel Sliwinski 11 , Thomy Tonia 12 , Jørgen Vestbo 13 , Kevin C. Wilson 14 and Jerry A. Krishnan (...) , Hospital Universitari Vall d’Hebron, Pg. Vall d’Hebron 119–129, Barcelona 08035, Spain. E-mail: mmiravitlles@vhebron.net @ERSpublications Different strategies are useful for the prevention of COPD exacerbations http://ow.ly/dqpD30daO4O Cite this article as: Wedzicha JA, Calverley PMA, Albert RK, et al. Prevention of COPD exacerbations: a European Respiratory Society/American Thoracic Society guideline. Eur Respir J 2017; 50: 1602265 [https://doi.org/10.1183/13993003.02265-2016]. ABSTRACT This document

American Thoracic Society2017